

1 **Comparative analysis of point-of-care lateral flow immunoassays for the detection of IgM and**
2 **IgG anti-SARS-CoV-2 antibodies in healthcare workers**

3
4 Danielle Dias Conte¹, Joseane Mayara Almeida Carvalho¹, Luciano Kleber de Souza Luna*¹,
5 Klinger Soares Faíco-Filho¹, Ana Helena Perosa², Nancy Bellei¹.

6
7 ¹Department of Medicine, Discipline of infectious diseases, Universidade Federal de São Paulo

8 ²Universidade Federal de São Paulo, Hospital São Paulo

9
10 *Corresponding author: Luciano Kleber de Souza Luna

11 Universidade Federal de São Paulo, Laboratório de Virologia Clínica. Rua Pedro de Toledo, Rua
12 Pedro de Toledo, 781 - Vila Clementino. 04039-032, São Paulo, SP, Brazil. Phone: + 55 11 5576-
13 4848, branch 2222. E-mail: lksluna@gmail.com

14

15

16 Abstract

17 Since the Coronavirus Disease 2019 (COVID-19) pandemic, Brazil has the third-highest number of
18 confirmed cases and the second-highest number of recovered patients. SARS-CoV-2 detection by
19 real-time RT-PCR is the gold standard in certified infrastructured laboratories. However, for large-
20 scale testing, diagnostics should be fast, cost-effective, widely available, and deployed for the
21 community, such as serological tests based on lateral flow immunoassay (LFIA) for IgM/IgG
22 detection. We evaluated three different commercial point-of-care (POC) LFIAs for anti-SARS-
23 CoV-2 IgM and IgG detection in capillary whole blood of 100 healthcare workers (HCW)
24 previously tested by RT-PCR: 1) COVID-19 IgG/IgM BIO (Bioclin, Brazil), 2) Diagnostic kit for
25 IgM/IgG Antibody to Coronavirus (SARS-CoV-2) (Livzon, China); and 3) SARS-CoV-2 Antibody
26 Test (Wondfo, China). A total of 84 positives and 16 negatives HCW were tested. The data was also
27 analyzed by the number of days after symptoms (DAS) in three groups: <30 (n=26), 30-59 (n=42),
28 and >59 (n=16). Overall detection was 85.71%, 47.62%, and 44.05% for Bioclin, Livzon, and
29 Wondfo, respectively, with a specificity of 100%, and 98.75% for Livzon on storage serum
30 samples. Bioclin was more sensitive ($p<0.01$), regardless of the DAS. Thus, the Bioclin can be used
31 as a POC test to monitor SARS-CoV-2 seroconversion in HCW.

32

33 **Keywords:** SARS-CoV-2 detection, point-of-care, lateral flow immunoassay, healthcare workers.

34

35 **1. Introduction**

36 After almost seven months since the Coronavirus Disease 2019 (COVID-19) pandemic, caused by
37 de the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Brazil reached, until late
38 August 2020, the second place in the number of confirmed cases. Currently (on September 15,
39 2020), in the third position, accounts for 4,345,610 confirmed cases, with 132,006 deaths, and is the
40 second country with the highest number of recovered patients (3,770,138) (Dong, Du, and Gardner,
41 2020).

42 The molecular detection of SARS-CoV-2 by real-time Reverse Transcription-Polymerase Chain
43 Reaction (RT-PCR) is the gold standard test but requires a certified laboratory infrastructure with
44 high-cost equipment and trained personnel. This structure is suitable, and of paramount importance,
45 for the diagnostic of hospitalized patients, as well as healthcare workers (HCW). However, for
46 large-scale testing, RT-PCR is not the best option. Therefore, COVID-19 diagnostic tests should be
47 fast, cost-effective, widely available, and deployed for the community. In general, those requisites
48 are achieved by serological tests based on lateral flow immunoassay (LFIA). Many LFIAs have
49 been described for the detection of IgM and IgG immunoglobulins against SARS-CoV-2 (Vashist,
50 2020). Immunoglobulin response against viral infection begins with an early and transient IgM
51 production, followed by a longer and lasting IgG response. In patients with COVID-19, the
52 production of IgM and IgG could be simultaneous and detected after two days of symptoms onset,
53 and could reach in some patients a plateau level after six days (Long et al., 2020; Zhao et al., 2020).
54 Moreover, the immunoglobulin levels are correlated positively with the severity of COVID-19
55 although the antibody response could be delayed in critical patients compared to non-critical cases
56 (Qu et al., 2020).

57 In the present study, we evaluated the sensitivity of three different commercial Point-of-care (POC)
58 LFIAs for anti-SARS-CoV-2 antibody detection, in HCW with confirmed tests (positive or
59 negative) for COVID-19 by RT-PCR assay.

60

61 **2. Material and methods**

62 Three commercial POC LFIAs for detection of anti-SARS-CoV-2 IgG and IgM were tested: 1)
63 COVID-19 IgG/IgM BIO (Bioclin, Brazil), 2) Diagnostic kit for IgM/IgG Antibody to Coronavirus
64 (SARS-CoV-2) (Livzon, China); and 3) SARS-CoV-2 Antibody Test (Wondfo, China). Bioclin and
65 Livzon LFIAs independently detect IgG and IgM, whereas Wondfo detects IgG and IgM combined.
66 A total of 100 HCW from University Hospital São Paulo, previously tested for SARS-CoV-2
67 infection by real-time RT-PCR, were enrolled in the study. From them, 84 were confirmed positive,
68 and 16, negative. Furthermore, 80 storage serum samples, collected during 2018 and 2019, were
69 also tested with Livzon LFIA, the only test available for this additional analysis.

70 The indicated volume of capillary whole blood for each test, collected preferably from the skin of
71 annular fingertip with a lancing device, was added immediately into the cassette sample wells,
72 following the addition of sample diluent according to the manufacturer instructions. All LFIAs were
73 tested simultaneously in the moment of blood draw of each investigated HCW. Similarly, the
74 recommended serum volume for testing the 80 storage serum samples with Livzon LFIA was also
75 applied accordingly. Results were read within 1-15 minutes.

76 Sensitivity was calculated as the proportion of positive results of LFIAs in relation to the positive
77 RT-PCR confirmed cases, and specificity was calculated as the proportion of LFIAs negative results
78 in relation to the negative RT-PCRs. The 95% confidence intervals (CI) of sensitivity and
79 specificity proportions were calculated by the modified Wald method. The results were also
80 analyzed according to the number of days after symptoms (DAS), distributed in three distinct
81 groups: <30 (n=26), 30-59 (n=42), and >59 (n=16). The proportion of results accounted for IgM
82 and IgG, alone or combined, regarding DAS, and pairwise comparison within LIFAs was analyzed
83 by Cochran's Q and McNemar tests, for a p -value <0.05. The analysis was made using software R
84 version 4.0.2 (Team, 2020).

85 The study was approved by the São Paulo hospital Research Ethics Committee (CEP n.
86 34371020.5.0000.5505).

87 3. Results

88 The age of investigated HCWs varied from 20 to 67 yeas (mean = 37.45, median = 36). Overall
89 detection of IgM and IgG, individually or combined, are described in table 1.

90

91 **Table 1:** Comparison of LFIA results with 84 positive RT-PCR for SARS-CoV-2.

LFIA	number / Sensitivity in % (95% CI)		
	IgG/IgM	IgM	IgG
Bioclin	72 / 85.71 (76.52-91.79)	46 / 54.76 (44.14-64.97)	72 / 85.71 (76.52-91.79)
Livzon	40 / 47.62 (37.28-58.17)	25 / 29.76 (21.01-40.29)	54 / 35.71 (26.28-46.40)
Wondfo	37 / 44.05 (33.92-54.70)	N.A.	N.A.

92 N.A., not available.

93

94 In general, Bioclin LFIA showed the highest sensitivity (85.71%), followed by Livzon (47.62%)
95 and Wondfo (44.05%).

96 In comparison to the 16 negative RT-PCR individuals, the sensitivity of all LFIAs was 100%
97 (77.31% to 100%, 95% CI). However, one storage serum sample from 2018 was IgG reagent by
98 Livizon LFIA and therefore the sensitivity of this additional test was 98.75% (92.59% to 99.99%,
99 95% CI).

100 The results according to the groups of DAS (<30, 30-59, and >59), are depicted in table 2.

101

102

103

104

105

106

107

108

109

110 **Table 2:** Comparison of LFIA results in time groups according to the days after symptoms (DAS).

Antibody	DAS	HCW	number (%)			<i>p</i> -valor
			Bioclin	Wondfo	Livzon	
IgM/IgG ¹	<30	26	22 (88.00)	14 (56.00)	13 (52.00)	0.0022*
	30-59	42	38 (88.37)	21 (48.84)	17 (39.53)	<0.001*
	>59	16	12 (75.00)	5 (31.25)	7 (43.75)	0.0131*
IgM ²	<30	26	19 (76.00)	NA	11 (44.00)	0.0047*
	30-59	42	21 (48.84)	NA	11 (25.58)	0.03892*
	>59	16	6 (37.50)	NA	3 (18.75)	0.0833
IgG ²	<30	26	22 (88.00)	NA	10 (44.00)	0.0005*
	30-59	42	38 (88.37)	NA	15 (34.88)	<0.001*
	>59	16	12 (75.00)	NA	5 (31.25)	0.0081

111 DAS, days after symptoms. HCW, healthcare workers.

112 * significant for $p < 0.05$

113 ¹Cochran's Q test, $p < 0.05$

114 ²McNemar test, $p < 0.05$

115

116 The Bioclin LFIA was significantly more sensitive, in comparison to Livzon and Wondfo,
117 regardless of the DAS or detection of IgM and IgG combined (Cochran's Q test, $p < 0.05$). The
118 posthoc analysis of pairwise comparisons with McNemar tests also have shown that Bioclin was
119 more sensitive than Livzon and Wondfo for IgM and IgG individually, and no differences were
120 observed between Livzon and Wondfo regardless of the DAS or immunoglobulin class (table 2).
121 The proportion of positives within each LFIA in relation to the DAS have shown any significant
122 difference for overall IgM and IgG detection (Bioclin, $p = 0.316$; Livzon, $p = 0.744$; Wondfo, $p = 0.33$),
123 IgG alone (Bioclin, $p = 0.316$; Livzon, $p = 0.894$), or IgM (Bioclin, $p = 0.054$; Livzon, $p = 0.208$),
124 although Bioclin is likely to be more sensitive for IgM in the group of <30 ($p = 0.054$).

125

126

127

128

129

130 **4. Discussion**

131 In the present study, we analyzed three different commercial LFIA for the detection of anti-SARS-
132 CoV-2 IgG and IgM in HCW. For the POC test format, capillary whole blood is more suitable than
133 serum or plasma and does not require a laboratory infrastructure for venous blood draw.

134 The use of POC based tests for rapid antibody detection can be helpful in identifying patients at
135 different stages of infection, due to the early production of IgM followed by IgG response, even
136 though in patients with COVID-19 the IgM and IgG response could be simultaneous. Our results
137 demonstrated that overall sensitivity achieved by Bioclin LFIA (85.71%) with whole blood samples
138 is compared to those obtained with serum or plasma, in contrast to Livzon and Wondfo LFIA
139 which showed sensitivities below 50% (Costa et al., 2020; Santos et al., 2020; Silveira et al., 2020;
140 Tuailon et al., 2020).

141 Similar to the results here described, Santos et al. (2020) have shown, for capillary whole blood, a
142 sensitivity of 55% for the Wondfo LFIA test in HCWs. On the other hand, the detection sensitivity
143 in serum samples was much higher (96%). In a larger study with hospitalized patients, Costa et al.
144 (2020) evaluated the Wondfo LFIA, in serum samples or plasma, and obtained a sensitivity of
145 85.8%. In another evaluation of the Wondfo LFIA, Wu et al. (2020) have shown a sensibility of
146 75.8% in serum samples. In the same manner, Livzon LFIA, when tested in serum samples of
147 hospitalized patients, presented a sensibility of 80% for IgM and 86.7 for IgG, with a specificity of
148 95% and 100% respectively.

149 An advantage of the present study is due to the fact that all LFIA were carried out simultaneously
150 at the time of blood draw from each HCW. On the other hand, a limitation of the study was the
151 impossibility of follow up on each HCW to observe possible variations in the detection of IgM and
152 IgG over time, or to expand the study to include hospitalized patients or low-income individuals
153 from the general community.

154

155

156 **5. Conclusion**

157 Bioclin LFIA demonstrated high sensitivity and specificity for IgG detection (85.71%), and a
158 reasonable detection of IgM (54.76%), with the use of capillary whole blood in HCW. On the other
159 hand, Livzon and Wondfo LFIAs presented overall sensitivity below 50%. Thus, the Bioclin LFIA
160 is a suitable POC test to monitor SARS-CoV-2 seroconversion in HCW.

161

162 **Acknowledgments**

163 J.M.A.C. and L.K.S.L. are fellows of the Coordenação de Aperfeiçoamento de Pessoal de Nível
164 Superior (CAPES), Brazil. D.D.C. is a fellow of the Conselho Nacional de Desenvolvimento
165 Científico e Tecnológico (CNPq), Brazil. We are grateful to Anderson Scorsato for the statistical
166 support.

167

168 **Declarations of interest:** none

169

170 **CRedit authorship contribution statement**

171 **Danielle D. Conte:** Validation, Investigation, Data Curation, Writing - Original Draft. **Joseane M.**
172 **A. Carvalho:** Investigation, Data Curation. **Luciano K. de Souza Luna:** Validation, Investigation,
173 Formal analysis, Writing - Review & Editing, Visualization. **Klinger S. Faício-Filho:** Investigation.
174 **Ana H. S. Perosa:** Investigation. **Nancy Bellei:** Conceptualization, Methodology, Resources,
175 Supervision, Writing - Review & Editing, Project administration, Funding acquisition.

176

177

178

179

180

181

182 **References**

- 183 Costa, S.F., Buss, L., Espinoza, E.P.S., Vieira, J.M., Jr., de Oliveira da Silva, L.C., de Souza, R.M., Neto, L.P., Porto,
184 A.P.M., Lazari, C., Dos Santos, V.A., da Silva Duarte, A., Nastri, A.C., da Costa Leite, G.F., Manuli, E.,
185 de Oliveira, M.S., Zampelli, D.B., Pastore, L.J., Segurado, A.C., Levin, A.S. and Sabino, E., 2020.
186 Performance of a qualitative rapid chromatographic immunoassay to diagnose COVID-19 in patients
187 in a middle-income country. *J Clin Virol* 131, 104592.
- 188 Dong, E., Du, H. and Gardner, L., 2020. An interactive web-based dashboard to track COVID-19 in real time.
189 *Lancet Infect Dis* 20, 533-534.
- 190 Long, Q.X., Liu, B.Z., Deng, H.J., Wu, G.C., Deng, K., Chen, Y.K., Liao, P., Qiu, J.F., Lin, Y., Cai, X.F., Wang, D.Q.,
191 Hu, Y., Ren, J.H., Tang, N., Xu, Y.Y., Yu, L.H., Mo, Z., Gong, F., Zhang, X.L., Tian, W.G., Hu, L., Zhang,
192 X.X., Xiang, J.L., Du, H.X., Liu, H.W., Lang, C.H., Luo, X.H., Wu, S.B., Cui, X.P., Zhou, Z., Zhu, M.M.,
193 Wang, J., Xue, C.J., Li, X.F., Wang, L., Li, Z.J., Wang, K., Niu, C.C., Yang, Q.J., Tang, X.J., Zhang, Y., Liu,
194 X.M., Li, J.J., Zhang, D.C., Zhang, F., Liu, P., Yuan, J., Li, Q., Hu, J.L., Chen, J. and Huang, A.L., 2020.
195 Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat Med* 26, 845-848.
- 196 Qu, J., Wu, C., Li, X., Zhang, G., Jiang, Z., Li, X., Zhu, Q. and Liu, L., 2020. Profile of IgG and IgM antibodies
197 against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *Clin Infect Dis*.
- 198 Santos, V.A.D., Rafael, M.M., Sabino, E.C. and Duarte, A., 2020. Sensitivity of the Wondfo One Step COVID-19
199 test using serum samples. *Clinics (Sao Paulo)* 75, e2013.
- 200 Silveira, M.F., Barros, A.J.D., Horta, B.L., Pellanda, L.C., Victora, G.D., Dellagostin, O.A., Struchiner, C.J.,
201 Burattini, M.N., Valim, A.R.M., Berlezi, E.M., Mesa, J.M., Ikeda, M.L.R., Mesenburg, M.A., Mantesso,
202 M., Dall'Agnol, M.M., Bittencourt, R.A., Hartwig, F.P., Menezes, A.M.B., Barros, F.C., Hallal, P.C. and
203 Victora, C.G., 2020. Population-based surveys of antibodies against SARS-CoV-2 in Southern Brazil.
204 *Nat Med* 26, 1196-1199.
- 205 Team, R.C. 2020. R: A Language and Environment for Statistical Computing, R Foundation for Statistical
206 Computing, Vienna, Austria.
- 207 Tuailon, E., Bollore, K., Pisoni, A., Debieesse, S., Renault, C., Marie, S., Groc, S., Niels, C., Pansu, N., Dupuy,
208 A.M., Morquin, D., Foulongne, V., Bourdin, A., Le Moing, V. and Van de Perre, P., 2020. Detection of
209 SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized
210 patients. *J Infect* 81, e39-e45.
- 211 Vashist, S.K., 2020. In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends.
212 *Diagnostics (Basel)* 10.
- 213 Wu, J.L., Tseng, W.P., Lin, C.H., Lee, T.F., Chung, M.Y., Huang, C.H., Chen, S.Y., Hsueh, P.R. and Chen, S.C.,
214 2020. Four point-of-care lateral flow immunoassays for diagnosis of COVID-19 and for assessing
215 dynamics of antibody responses to SARS-CoV-2. *J Infect*.
- 216 Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., Qian, S., Hong, C., Wang,
217 F., Liu, Y., Wang, Z., He, Q., Li, Z., He, B., Zhang, T., Fu, Y., Ge, S., Liu, L., Zhang, J., Xia, N. and Zhang,
218 Z., 2020. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. *Clin Infect*
219 *Dis*.